Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma, Alveolar 1Penile Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Mesothelioma, Malignant 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoma 1

Interventions

Cisplatin 10pembrolizumab 8Carboplatin 8Paclitaxel 6durvalumab 5Pemetrexed 51-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5osimertinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Taxes 3Nivolumab 3Gemcitabine 3Docetaxel 3Bevacizumab 3cabozantinib 2atezolizumab 2Sunitinib 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Radiation 2Platinum 2Immunoglobulin G 2Disulfides 2CP protocol 2Biopsy 21,2-diaminocyclohexaneplatinum II citrate 2trifluridine tipiracil drug combination 1tremelimumab 1relatlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma × BAY 1895344 × Clear all
NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡